Aravive (ARAV) - Get Reportshares jumped on Thursday after the oncology-pharmaceutical specialist reported progress in a trial of a treatment for kidney cancer.<\/p>\n
The Houston company cited positive initial results from the Phase 1b study in patients dosed with 15mg\/kg of AVB-500 in combination with cabozantinib who have advanced-stage kidney cancer. <\/p>\n
The data in three evaluable patients showed that AVB-500 was well tolerated with no unexpected findings,\" the company said.<\/p>\n
Aravive shares recently traded at $6.66, up 25%. It had been down 14% in the six months through the close of Wednesday trading.<\/p>\n
Now the company plans to expand the dosing of 15mg\/kg of AVB-500 to an additional three patients to determine the potential of initiating the Phase 2 portion with this dose, it said. <\/p>\n
The company also expects to continue to investigate higher doses of AVB-500 in the Phase 1b to obtain additional safety\" and other data.<\/p>\n
The clinical data indicate that AVB-500 in combination with anticancer therapies \"may have the potential to be used in a range of different cancers.Chief Executive Gail McIntyre said in a statement.<\/p>\n
In other drug news Thursday, Eli Lilly (LLY) - Get Reportreceived breakthrough status for its donanemab treatment for Alzheimers disease from the FDA.<\/p>\n
That speeds the Food and Drug Administrations consideration of the drug for marketing clearance.<\/p>\n
Earlier this month the FDA approved Biogens (BIIB) - Get ReportAduhelm to treat Alzheimers. That drug, too, had breakthrough status.<\/p>\n
Analysts upgraded Biogen after the move, with Bernsteins Ronny Gal lifting his rating to outperform from market perform.<\/p>\n
<\/p>\n
Read the original:<\/p>\n
Aravive Higher on Progress in Phase 1b Trial of Kidney-Cancer Drug - TheStreet<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Aravive (ARAV) - Get Reportshares jumped on Thursday after the oncology-pharmaceutical specialist reported progress in a trial of a treatment for kidney cancer. The Houston company cited positive initial results from the Phase 1b study in patients dosed with 15mg\/kg of AVB-500 in combination with cabozantinib who have advanced-stage kidney cancer Continue reading